Posts

Posted on

Semtech Expands Industry’s Most Comprehensive 5G Wireless Front Haul Portfolio With its Latest 50Gbps Tri-Edge™ CDR IC Solution

Semtech Expands Industry’s Most Comprehensive 5G Wireless Front Haul Portfolio With its Latest 50Gbps Tri-Edge™ CDR IC Solution

GN2256 is a bidirectional Tri-Edge CDR with integrated differential EML driver for 50Gbps SFP56 PAM4 5G wireless optical modules

CAMARILLO, Calif.–(BUSINESS WIRE)–Semtech Corporation (Nasdaq: SMTC), a leading supplier of high performance analog and mixed-signal semiconductors and advanced algorithms, today announced sampling of the newest member of its Tri-Edge™ CDR portfolio, the GN2256. Integrating Semtech’s proven Tri-Edge CDR platform with a differential EML (Externally Modulated Laser) driver, the GN2256 is the industry’s first such IC solution to enable 50Gbps PAM4 Fixed-WDM (Wavelength Division Multiplexing), Tunable WDM and Silicon Photonics optical modules. As with all Tri-Edge ICs, the GN2256 offers ultra-low latency, low power and use of low cost 25Gbps bandwidth optics to operate at 50Gbps PAM4.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210407005095/en/

Semtech launches its latest 50Gbps Tri-Edge™ CDR IC Solution (Photo: Business Wire)

Semtech launches its latest 50Gbps Tri-Edge™ CDR IC Solution (Photo: Business Wire)

The approach to expanding 5G wireless infrastructure bandwidth differs based on geographic region, deployment area considerations and carrier preferences. This often requires different types of optical modules in 5G wireless front haul links. In regions where it is typically difficult to install more fiber or reduce overhead costs, carriers utilize “colored” optical modules that send and receive multiple signals using differing wavelengths on a single fiber. These optical modules are also referred to as WDM optical modules and are critical for the 5G wireless infrastructure, especially for countries like Japan, Korea and the U.S. The GN2256 combines Semtech’s proprietary analog Tri-Edge technology with enhanced laser driver compensation to enable IEEE and Open Eye MSA compliant optical modules over industrial temperature ranges. Semtech’s Tri-Edge 5G platform addresses the full range of optical modules needed for all regions by enabling multiple types of SFP56 optical modules operating at 50Gbps PAM4.

“With the introduction of the GN2256 Tri-Edge IC, Semtech has established itself as the leader in 5G wireless front haul deployments with a truly differentiated and comprehensive IC portfolio. Semtech is a one-stop shop for our optical module partners and system vendors to enable worldwide 5G wireless front haul deployments,” said Raza Khan, senior market manager for Semtech’s Signal Integrity Products Group.

The GN2256 is now available for sampling and Semtech will also offer a complete Reference Design Kit (RDK) including complete module-level firmware to enable rapid adoption of Semtech’s solution.

Semtech’s 5G wireless Tri-Edge CDR portfolio includes:

  • GN2255: Bidirectional 50Gbps PAM4 Tri-Edge CDR with Integrated DML driver
  • GN2256: Bidirectional 50Gbps PAM4 Tri-Edge CDR with Integrated Diff EML driver

Semtech’s comprehensive 5G wireless ClearEdge® CDR portfolio includes:

  • GN2152: Bidirectional 24-28Gbps ClearEdge CDR with Integrated DML Driver
  • GN2146: Bidirectional 24-28Gbps ClearEdge CDR with Integrated EML / MZM Driver
  • GN2154: Bidirectional 24-28Gbps ClearEdge CDR with Integrated SE EML Driver
  • GN2148: Single 24-28Gbps ClearEdge CDR with Integrated VCSEL Driver
  • GN2149: Single 24-28Gbps ClearEdge CDR with Integrated TIA

Semtech’s 5G wireless FiberEdge TIA portfolio includes:

  • GN1086: 24-28Gbps FiberEdgeTIA
  • GN1089 / GN1800: 50Gbps PAM4 FiberEdge TIA

About Semtech’s Optical Products

Semtech’s optical networking product platforms provide high-performance signal integrity for optical module solutions used by leading companies in the data center/enterprise networking, wireless infrastructure and passive optical network/Fiber to the markets. For more information, visit www.semtech.com/optical.

About Semtech

Semtech Corporation is a leading supplier of high performance analog and mixed-signal semiconductors and advanced algorithms for infrastructure, high-end consumer and industrial equipment. Products are designed to benefit the engineering community as well as the global community. The Company is dedicated to reducing the impact it, and its products, have on the environment. Internal green programs seek to reduce waste through material and manufacturing control, use of green technology and designing for resource reduction. Publicly traded since 1967, Semtech is listed on the NASDAQ Global Select Market under the symbol SMTC. For more information, visit http://www.semtech.com.

Forward-Looking and Cautionary Statements

All statements contained herein that are not statements of historical fact, including statements that use the words “will,” “designed to,” or other similar words or expressions, that describe Semtech Corporation’s or its management’s future plans, objectives or goals are “forward-looking statements” and are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Semtech Corporation to be materially different from the historical results and/or from any future results or outcomes expressed or implied by such forward-looking statements. Such factors are further addressed in Semtech Corporation’s annual and quarterly reports, and in other documents or reports, filed with the Securities and Exchange Commission (www.sec.gov) including, without limitation, information under the captions “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors.” Semtech Corporation assumes no obligation to update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release, except as required by law.

Semtech, the Semtech logo and ClearEdge are registered trademarks or service marks, and Tri-Edge is a trademark or service mark, of Semtech Corporation or its affiliates.

SMTC-P

Linh Dinh

Semtech Corporation

(805) 250-1263

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Networks Semiconductor Mobile/Wireless Technology Telecommunications

MEDIA:

Photo
Photo
Semtech launches its latest 50Gbps Tri-Edge™ CDR IC Solution (Photo: Business Wire)
Posted on

Better Therapeutics to Become Publicly Traded Prescription Digital Therapeutics Company via Merger with Mountain Crest Acquisition Corp. II

Better Therapeutics to Become Publicly Traded Prescription Digital Therapeutics Company via Merger with Mountain Crest Acquisition Corp. II

Transaction values Better Therapeutics at a pro forma fully diluted enterprise value of approximately $187 million with existing Better Therapeutics shareholders rolling over 100% of their equity into equity of the combined company

Transaction expected to provide up to $113 million of cash proceeds, including a fully committed $50 million PIPE and up to $57.5 million of cash held in the Mountain Crest II trust account assuming no redemptions

The PIPE was led by Farallon Capital Management, RS Investments, Sectoral Asset Management, and Monashee Investment Management, with participation from other undisclosed investors

Better Therapeutics also received commitments through a separate private placement of $6 million

Transaction is expected to close in the summer of 2021, with the combined company expected to trade on the Nasdaq Capital Market under the symbol “BTTX”

SAN FRANCISCO & NEW YORK–(BUSINESS WIRE)–
Better Therapeutics, Inc. a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, will go public, raising up to $113 million to advance its robust pipeline of products to treat cardiometabolic diseases, conditions which cost the U.S. healthcare system almost $500 billion each year. Better Therapeutics has entered into a definitive merger agreement with Mountain Crest Acquisition Corp II (Nasdaq: MCAD; “Mountain Crest II”), a publicly traded special purpose acquisition corporation or SPAC. The transaction values Better Therapeutics at a pro forma fully diluted enterprise value of approximately $187 million with existing Better Therapeutics shareholders rolling over 100% of their equity into equity of the combined company. Upon completion of the transaction, which is anticipated in the summer 2021, the combined company will operate as Better Therapeutics and securities are expected to be listed on Nasdaq under the symbol “BTTX.”

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210407005486/en/

The transaction includes a $50 million private investment in public equity (PIPE) from leading healthcare investors and thought leaders that are led by Farallon Capital Management, RS Investments, Sectoral Asset Management, and Monashee Investment Management, with participation from other undisclosed investors. Better Therapeutics has also received commitments through a separate private placement of $6 million.

The proceeds of the transaction will be used to advance Better Therapeutics’ lead product for the treatment of type 2 diabetes, BT-001, to marketing authorization by the U.S. Food and Drug Administration and advance Better Therapeutics’ pipeline of prescription digital therapeutics for a range of cardiometabolic diseases.

Better Therapeutics Overview

Better Therapeutics has created a platform for the development of prescription digital therapeutics (PDT) for the treatment of diabetes, heart disease and other cardiometabolic conditions. The Better Therapeutics platform blends clinical, behavioral and psychological inputs into a series of therapy lessons and skill-building modules designed to isolate and shift the underlying thoughts and beliefs which guide diet and lifestyle behaviors that are the root causes of a wide range of cardiometabolic diseases. The delivery of behavioral therapy enables changes in neural pathways of the brain and leads to behavioral change. These therapies and the resulting changes hold the potential to lower healthcare costs to treat these conditions and improve patient health.

Better Therapeutics’ first PDT (BT-001) is being evaluated in a pivotal trial as a treatment for type 2 diabetes used under physician supervision. It is anticipated that following marketing authorization, primary care providers will prescribe, and insurers will reimburse Better Therapeutics’ PDTs much like they would a traditional medication.

Management Comments

David Perry, Co-founder and Executive Chairman of Better Therapeutics commented, “Today, 34 million people in the U.S. have been diagnosed with type 2 diabetes and another 88 million are considered prediabetic. We believe we have an immense opportunity to fundamentally change the treatment paradigm for these individuals with our PDT platform. Multiple studies published in peer-reviewed medical journals support our proposition that our digital therapeutics have the potential to improve blood glucose and HbA1c levels similar to drug therapies. We believe that by addressing the underlying causes of disease, our products have the potential to improve patient health while reducing treatment costs.”

Kevin Appelbaum, Co-founder and Chief Executive Officer of Better Therapeutics, added, “This is a unique time to build a company like Better Therapeutics. Patients, doctors and insurers have grown increasingly comfortable with digitally delivered solutions, including prescription digital therapeutics, and we are uniquely positioned to change the way some of the most prevalent and costly diseases are treated.”

“I am thrilled to take the second Mountain Crest SPAC to the next phase of our deal process, and the founding team at Better Therapeutics has a track record of creating successful companies by focusing on large and disruptive market opportunities,” said Dr. Suying Liu, Chairman and Chief Executive Officer of Mountain Crest II. “We are excited to partner with them to accelerate the development and commercialization of the Better Therapeutics platform, which aims to deliver life changing outcomes to patients,” Dr. Liu continued.

Key Transaction Terms

The transaction, which has been unanimously approved by the Boards of Directors of Better Therapeutics and Mountain Crest II, is subject to approval by the Better Therapeutics’ stockholders, Mountain Crest II’s stockholders and other customary closing conditions. The proposed business combination is expected to be completed in the summer of 2021.

A more detailed description of the transaction terms and a copy of the definitive merger agreement will be included in a Current Report on Form 8-K to be filed by Mountain Crest II with the United States Securities and Exchange Commission (“SEC”). Mountain Crest II will file a registration statement (which will contain a joint proxy statement/prospectus) with the SEC in connection with the transaction.

Advisors

Cowen is acting as exclusive financial advisor and capital markets advisor to Better Therapeutics. Lake Street is also serving as a capital markets advisor. Goodwin Procter LLP is acting as legal counsel to Better Therapeutics in the transaction. Chardan is acting as exclusive M&A advisor and financial advisor to Mountain Crest II. Loeb & Loeb LLP is acting as legal counsel to Mountain Crest II. Cowen is acting as sole placement agent to Mountain Crest II on the PIPE. Shearman & Sterling LLP is acting as legal counsel to the placement.

Investor Presentation

A prerecorded presentation made by the management teams of both Better Therapeutics and Mountain Crest II regarding the transaction will be available on the website of Better Therapeutics at www.BetterTx.com. Mountain Crest II will also file the presentation with the SEC in a Current Report on Form 8-K, which will be accessible at www.sec.gov.

About Better Therapeutics

Better Therapeutics is a prescription digital therapeutics (PDT) company delivering a novel form of behavior-based therapy to address the root causes of cardiometabolic diseases. Better Therapeutics has developed a proprietary platform for the development of FDA-regulated, software-based therapies for type 2 diabetes, heart disease and other conditions. The cognitive behavioral therapy delivered by Better Therapeutics’ PDT enables changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics’ PDTs are intended to be prescribed by physicians and reimbursed like traditional medicines. For more information, visit: bettertx.com

About Mountain Crest Acquisition Corp. II

Mountain Crest Acquisition Corp. II is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Mountain Crest II ‘s efforts to identify a prospective target business will not be limited to a particular industry or geographic region, although the company intends to focus on operating businesses in North America.

Important Information about the Proposed Business Combination and Where to Find It

In connection with the proposed business combination, Mountain Crest II will file a registration statement on Form S-4 containing a proxy statement/prospectus (the “Form S-4”) with the Securities and Exchange Commission (the “SEC”). The Form S-4 will include a proxy statement to be distributed to holders of Mountain Crest II’s common stock in connection with Mountain Crest II’s solicitation of proxies for the vote by Mountain Crest II’s shareholders with respect to the proposed transaction and other matters as described in the Form S-4, as well as the prospectus relating to the offer of securities to be issued to Better Therapeutics’ stockholders in connection with the proposed business combination. After the Form S-4 has been filed and declared effective, Mountain Crest II will mail a definitive proxy statement, when available, to its stockholders. Investors and security holders and other interested parties are urged to read the Form S-4, any amendments thereto and any other documents filed with the SEC carefully and in their entirety when they become available because they will contain important information about Mountain Crest II, Better Therapeutics and the proposed business combination. Additionally, Mountain Crest II will file other relevant materials with the SEC in connection with the business combination. Copies of these documents may be obtained free of charge at the SEC’s web site at www.sec.gov. Securityholders of Mountain Crest II are urged to read the Form S-4 and the other relevant materials when they become available before making any voting decision with respect to the proposed business combination because they will contain important information. The information contained on, or that may be accessed through, the website referenced in this press release is not incorporated by reference into, and is not a part of, this press release.

Participants in the Solicitation

Mountain Crest and Better Therapeutics and their respective directors and executive officers may be deemed participants in the solicitation of proxies with respect to the proposed business combination under the rules of the SEC. Securityholders may obtain more detailed information regarding the names, affiliations, and interests of certain of Mountain Crest’s executive officers and directors in the solicitation by reading Mountain Crest’s Form S-4 and other relevant materials filed with the SEC in connection with the proposed business combination when they become available. Information about Mountain Crest II’s directors and executive officers and their ownership of Mountain Crest II common stock is set forth in Mountain Crest II’s annual report on Form 10-K for the year ended December 31, 2020, dated March 30, 2021 , as modified or supplemented by any Form 3 or Form 4 filed with the SEC since the date of that filing. Other information regarding the interests of Mountain Crest II’s participants in the proxy solicitation, which in some cases, may be different than those of their stockholders generally, will be set forth in the Form S-4 relating to the proposed business combination when it becomes available. These documents can be obtained free of charge at the SEC’s web site at www.sec.gov.

Better Therapeutics and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the stockholders of Mountain Crest II in connection with the proposed business combination. A list of the names of such directors and executive officers and information regarding their interests in the proposed business combination will be included in the Form S-4 for the proposed business combination.

Non-Solicitation

This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

Forward-Looking Statements

Certain statements made in this press release are “forward-looking statements” within the meaning of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, including statements about the parties’ ability to close the proposed business combination and related transactions, the anticipated benefits of the proposed business combination, and the financial condition, results of operations, earnings outlook and prospects of Mountain Crest II and/or the proposed business combination and related transactions and may include statements for the period following the consummation of the proposed business combination and related transactions. In addition, any statements that refer to projections (including EBITDA, adjusted EBITDA, EBITDA margin and revenue projections), forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements are typically identified by words such as “plan,” “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should,” “would” and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking.

The forward-looking statements are based on the current expectations of the management of Mountain Crest II and Better Therapeutics, as applicable, and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements including: risks related to Better Therapeutics’ strategies and its PDTs, such as the willingness of the FDA to approve PDTs and insurance companies to reimburse their use; the ability to complete the proposed business combination due to the failure to obtain approval from Mountain Crest II’s stockholders or satisfy other closing conditions in the definitive merger agreement; the amount of any redemptions by existing holders of Mountain Crest II’s common stock; the ability to recognize the anticipated benefits of the business combination; other risks and uncertainties included under the header “Risk Factors” in the registration statement on Form S-4 to be filed by Mountain Crest II, in the final prospectus of Mountain Crest II for its initial public offering dated January 7, 2021 and its annual report on Form 10-K for the year ended December 31, 2020; and in Mountain Crest II’s other filings with the SEC.

Heidi Chokeir, Ph.D.

[email protected]

+1 619 203 5391

KEYWORDS: California New York United States North America

INDUSTRY KEYWORDS: Professional Services Mental Health Health Fitness & Nutrition Finance General Health Pharmaceutical

MEDIA:

Logo
Logo
Logo
Logo
Posted on

Evolv Technology Honored with 2021 Artificial Intelligence Product Excellence Award

First AI-enabled Crowd Security Screening System That Can Differentiate Between Weapons and Personal Items

WALTHAM, Mass., April 07, 2021 (GLOBE NEWSWIRE) — Evolv Technology, the leader in AI touchless security screening, today announced that Evolv Express® has been named a winner in this year’s Artificial Intelligence Excellence Awards program.

In its inaugural year, the Business Intelligence Group organized the Artificial Intelligence Excellence Awards to recognize organizations, products and people who bring artificial intelligence (AI) to the market and apply it to solve real problems. The role of AI was already transforming many aspects of our lives and culture before the COVID-19 pandemic, and now companies are escalating their reliance on AI to build new processes, launch new services or deploy the AI of strategic vendors.

As the world’s only AI-enabled touchless screening system on the market, Evolv Express uses advanced sensors and machine learning to screen for concealed weapons, differentiating weapons from personal items. Earning the top spot in the award program’s ‘automatic targeted recognition’ category, the system transforms security screening as we know it. Traditional, decades-old metal detector technology was not built to accommodate for technical advances in personal items, such as cell phones or titanium implants, or today’s increasing threats to crowds in public spaces, which are considered soft targets. Evolv Express screens ten times faster than legacy metal detectors with an unparalleled 3,600 people per hour per system at a 70% reduction in cost. Built on its Evolv Cortex AI™ software platform, Evolv is continually improving the security posture for customers through machine learning and analytical insights on-demand.

“Our system reflects a fundamental rethinking of physical security in order to identify threats more effectively while improving the experience of sports fans, patrons, visitors, employees, students and staff, and others,” said Evolv Technology Co-founder and Head of Advanced Technology Michael Ellenbogen. “With Evolv’s AI-enabled software, we’re able to respond to changing customer requirements swiftly and efficiently. It’s an honor for our system to be recognized for this AI Excellence Award.”

“We’re especially proud of Evolv Chief Scientist Dr. Alec Rose and his team for driving such innovative advancements in the area of physical security,” Ellenbogen continued. “By doing so, we believe they are rewriting the standards for what’s required in providing best-in-class human security around the world.”

As the pandemic has unfolded, organizations have had to reevaluate their safety operations when it comes to addressing threats from weapons violence and health risks. In reviewing security processes, antiquated screening products and methods like metal detectors, pat downs and hand wands have become potential risk factors for re-opening ticketed venues, companies, schools and other venues. These organizations can benefit from security that provides a seamless and touchless experience. Express uses artificial intelligence software and advanced digital sensors that are highly accurate, discreet and deliver significantly more throughput than outdated, analog technologies. Importantly, the AI-enabled system allows for rapid integration of new capabilities such as analytics and thermal scanning.

The world’s most iconic venues and companies place their trust in Evolv to protect their employees and visitors including Uber, Lincoln Center, L.L. Bean, Six Flags, and hundreds of others. Evolv’s systems have been used to screen more than 50 million people, second only to the Department of Homeland Security’s Transportation Security Administration in screening people in the U.S.

About Evolv Technology

Evolv Technology is the world’s leading provider of AI touchless security screening systems that enhance safety without sacrificing the visitor, student and employee experience. Built on top of its Evolv Cortex AI™ software platform, the company provides an array of AI touchless screening technologies for weapons detection, identity verification and health-related threats.

Led by a team of security industry leaders with a track record for delivering first-to-market products, Evolv’s investors include Bill Gates, Florida Governor Jeb Bush’s firm, Finback Investment Partners, DCVC, General Catalyst Partners, Lux Capital, SineWave Ventures, Motorola Solutions and STANLEY Ventures. The company’s partners include Motorola Solutions, STANLEY Security and Johnson Controls. Evolv Express® has earned industry accolades such as the 2020 Edison Awards™, two Campus Safety 2020 BEST Awards, Campus Security & Life Safety magazine’s Secure Campus 2020 Awards and Best Places to Work by Inc. Magazine and Built in Boston.

Evolv Technology, Evolv Express®, and Evolv Cortex AI™ are registered trademarks or trademarks of Evolv Technologies, Inc. in the United States and other jurisdictions.
For more information, visit https://evolvtechnology.com.

Forward-Looking Statements

This document contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed transaction between NewHold Investment Corp. (“NewHold”) and Evolv Technologies, Inc. (“Evolv”). These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of NewHold’s securities, (iii) the failure to satisfy the conditions to the consummation of the transaction, including the adoption of the Agreement and Plan of Merger, dated as of March 5, 2021 (the “Merger Agreement”), by and among NewHold, Evolv and NHIC Merger Sub Inc., a Delaware corporation and a direct wholly owned subsidiary of NewHold, by the stockholders of NewHold, the satisfaction of the minimum trust account amount following redemptions by NewHold’s public stockholders and the receipt of certain governmental and regulatory approvals, (iv) the lack of a third party valuation in determining whether or not to pursue the transaction, (v) the inability to complete the PIPE investment in connection with the transaction, (vi) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement, (vii) the effect of the announcement or pendency of the transaction on Evolv Aviation’s business relationships, operating results and business generally, (viii) risks that the proposed transaction disrupts current plans and operations of Evolv and potential difficulties in Evolv employee retention as a result of the transaction, (ix) the outcome of any legal proceedings that may be instituted against Evolv or against NewHold related to the Merger Agreement or the transaction, (x) the ability to maintain the listing of NewHold’s securities on a national securities exchange, (xi) the price of NewHold’s securities may be volatile due to a variety of factors, including changes in the competitive and highly regulated industries in which NewHold plans to operate or Evolv operates, variations in operating performance across competitors, changes in laws and regulations affecting NewHold’s or Evolv’s business and changes in the combined capital structure, (xii) the ability to implement business plans, forecasts, and other expectations after the completion of the transaction, and identify and realize additional opportunities, and (xiii) the risk of downturns and a changing regulatory landscape in Evolv’s highly competitive industry. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of NewHold’s registration on Form S-1 (File No. 333-239822), the registration statement on Form S-4 discussed above and other documents filed by NewHold from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law NewHold and Evolv assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither NewHold nor Evolv gives any assurance that either NewHold or Evolv or the combined company will achieve its expectations.

Any financial projections in this communication are forward-looking statements that are based on assumptions that are inherently subject to significant uncertainties and contingencies, many of which are beyond NewHold’s and Evolv’s control. While all projections are necessarily speculative, NewHold and Evolv believe that the preparation of prospective financial information involves increasingly higher levels of uncertainty the further out the projection extends from the date of preparation. The assumptions and estimates underlying the projected results are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the projections. The inclusion of projections in this communication should not be regarded as an indication that NewHold and Evolv, or their representatives, considered or consider the projections to be a reliable prediction of future events.


Media Contacts:


Jennifer Torode
[email protected]



Posted on

SmileDirectClub Announces New Lifetime Smile Guarantee™

Industry-First Program Bolsters Customer Experience, Giving Teeth Straightening Customers Straighter, Healthier Smiles for Life

NASHVILLE, Tenn., April 07, 2021 (GLOBE NEWSWIRE) — In honor of World Health Day, SmileDirectClub, Inc. (Nasdaq: SDC), the next generation oral care company with the first medtech platform for teeth straightening, announced today its new Lifetime Smile Guarantee™, an industry-first offering that guarantees its customers a straighter smile for life. As a leader in oral care innovation, SmileDirectClub is committed to helping customers achieve a healthier smile, which in turn leads to improved overall health.

Customers who complete clear aligner therapy with SmileDirectClub and order two retainers per year by maintaining their SmileDirectClub retainer subscription, will qualify for the Lifetime Smile Guarantee. The guarantee ensures customers can qualify for one free set of aligners on an annual basis, if determined necessary by the prescribing dentist or orthodontist, to achieve the desired results.

“Our Lifetime Smile Guarantee provides a tremendous value to our customer. It ensures SmileDirectClub’s premium, doctor-directed treatment is guaranteed for life and that our customers continue to receive our unparalleled customer support well beyond their initial treatment,” said John Sheldon, Chief Marketing Officer of SmileDirectClub. “We pride ourselves on providing consumers the best option in teeth straightening and a superior customer experience without the 3x markup of our leading competitor. This innovative offering is unmatched in the industry, extends the lifetime customer relationship for SmileDirectClub, and highlights just one of the many ways becoming a member of the Club delivers the best possible experience.”

The Lifetime Smile Guarantee was designed to deliver even more value to SmileDirectClub Club Members who use the company’s pioneering telehealth platform for teeth straightening by ensuring eligible customers will never have to pay again to straighten their smile.

“Teeth naturally move throughout a person’s life, even after completing any teeth straightening service,” said Dr. Jeffrey Sulitzer, Chief Clinical Officer at SmileDirectClub. “Our Lifetime Smile Guarantee ensures our Club Members can keep their new smile for life and reap the additional benefits from a lifelong straighter smile, including the ability to improve oral health and potentially reduce chronic inflammation of the gums which helps avoid diseases like diabetes, coronary artery disease, and rheumatoid arthritis.”

Since launching in the U.S. in 2014, SmileDirectClub has become one of the fastest-growing health technology companies, serving well over one million customers around the world.

About SmileDirectClub

SmileDirectClub, Inc. (Nasdaq: SDC) (“SmileDirectClub”) is an oral care company and creator of the first medtech platform for teeth straightening, now also offered directly via dentist and orthodontists’ offices. Through its cutting-edge teledentistry technology and vertically integrated model, SmileDirectClub is revolutionizing the oral care industry, offering consumers the ability to get clinically safe and effective treatment but without the 3x markup associated with traditional orthodontics. SmileDirectClub’s mission is to democratize access to a smile each and every person loves by making it affordable and convenient for everyone. SmileDirectClub is headquartered in Nashville, Tennessee and operates in the U.S., Canada, Mexico, Australia, New Zealand, United Kingdom, Ireland, Germany, Austria, Hong Kong, Singapore, Spain and Mexico. For more information, please visit SmileDirectClub.com.

Contact: SmileDirectClub Media Relations: [email protected]

 



Posted on

Titan International, Inc. Announces Proposed Offering of Senior Secured Notes

PR Newswire

QUINCY, Ill., April 7, 2021 /PRNewswire/ — Titan International, Inc. (NYSE: TWI) (“Titan” or the “Company”) today announced its intention to offer through a private placement, subject to market and other conditions, $400 million aggregate principal amount of its Senior Secured Notes due 2028 (the “2028 Notes”). The 2028 Notes are being offered by the initial purchasers only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States in compliance with Regulation S under the Securities Act.

Titan intends to use the net proceeds from the offering to finance the redemption of its 6.50% Senior Secured Notes due 2023 (the “2023 Notes”), including all call premiums, accrued interest, costs and expenses associated therewith, which are being called for redemption in accordance with the applicable provisions of the indenture governing the 2023 Notes.  The redemption of the 2023 Notes is conditional upon the closing of the offer and sale of the 2028 Notes. 

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the 2028 Notes. Any offers of the 2028 Notes will be made only by means of a private offering circular. The 2028 Notes have not been registered under the Securities Act or the securities laws of any jurisdiction and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements. This press release is for information purposes only and does not constitute a notice of redemption or other offer to purchase or a solicitation of an offer to purchase any of the 2023 Notes.


Safe harbor statement:
 
This press release contains forward-looking statements regarding the Company’s intention to offer, subject to market and other conditions, the 2028 Notes; the use of the proceeds for the 2028 Notes; and the Company’s intention to redeem the 2023 Notes. These forward-looking statements are covered by the safe harbor for “forward-looking statements” provided by the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “plan,” “would,” “could,” “potential,” “may,” “will,” and other similar expressions are intended to identify forward-looking statements, which are generally not historical in nature. These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effect on us. Although we believe the assumptions upon which these forward-looking statements are based are reasonable, these assumptions are subject to significant risks and uncertainties, and are subject to change based on various factors, some of which are beyond Titan International, Inc.’s control. As a result, any of these assumptions could prove to be inaccurate and the forward-looking statements based on these assumptions could be incorrect, and actual results may vary materially from those indicated or anticipated by such statements. The inclusion of such statements should not be regarded as a representation of such plans, estimates or expectations will be achieved. The matters discussed in these forward-looking statements are subject to risks, uncertainties, and other factors that could cause actual results and trends to differ materially from those made, projected, or implied in or by the forward-looking statements depending on a variety of uncertainties or other factors including, but not limited to, the Company’s ability to refinance its notes due in 2023 on favorable terms to it or at all due to prevailing market conditions or otherwise; the continued effect of the COVID-19 pandemic on our operations and financial performance; changes in the Company’s end-user markets into which the Company sells its products as a result of domestic and world economic or regulatory influences or otherwise; changes in the marketplace, including new products and pricing changes by the Company’s competitors; the Company’s ability to maintain satisfactory labor relations; unfavorable outcomes of legal proceedings; the Company’s ability to comply with current or future regulations applicable to the Company’s business and the industry in which it competes or any actions taken or orders issued by regulatory authorities; availability and price of raw materials; levels of operating efficiencies; the effects of the Company’s indebtedness and its compliance with the terms thereof; changes in the interest rate environment and their effects on the Company’s outstanding indebtedness; unfavorable product liability and warranty claims; actions of domestic and foreign governments, including the imposition of additional tariffs; geopolitical and economic uncertainties relating to the countries in which the Company operates or does business; risks associated with acquisitions, including difficulty in integrating operations and personnel, disruption of ongoing business, and increased expenses; results of investments; the effects of potential processes to explore various strategic transactions, including potential dispositions; fluctuations in currency translations; risks associated with environmental laws and regulations; risks relating to our manufacturing facilities, including that any of our material facilities may become inoperable; risks relating to financial reporting, internal controls, tax accounting, and information systems; and the other risks and factors detailed in the Company’s periodic reports filed with the Securities and Exchange Commission, including the disclosures under “Risk Factors” in those reports. These forward-looking statements are made only as of the date hereof. The Company cautions that any forward-looking statements included in this press release are subject to a number of risks and uncertainties, and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events, or for any other reason, except as required by law.


About Titan

Titan International, Inc. (NYSE: TWI) is a leading global manufacturer of off-highway wheels, tires, assemblies, and undercarriage products. Headquartered in Illinois, the Company globally produces a broad range of products to meet the specifications of original equipment manufacturers (OEMs) and aftermarket customers in the agricultural, earthmoving/construction, and consumer markets. For more information, visit www.titan-intl.com.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/titan-international-inc-announces-proposed-offering-of-senior-secured-notes-301264055.html

SOURCE Titan International, Inc.

Posted on

Tinkerbell, an Equinix Open Source Project, Empowers Developers to Deploy and Manage Foundational Infrastructure at Global Scale

All-in-One Bare Metal Provisioning Platform & CNCF Sandbox Project Simplifies Heterogenous Digital Infrastructure

PR Newswire

REDWOOD CITY, Calif., April 7, 2021 /PRNewswire/ — Equinix, Inc. (Nasdaq: EQIX), the world’s digital infrastructure company™, today announced that Tinkerbell, an all-in-one open source bare metal provisioning platform, has added significant new features since joining the Cloud Native Computing Foundation (CNCF) Sandbox program. As a CNCF project sponsored by Equinix, Tinkerbell has also gained ecosystem adoption among cloud native digital leaders for its ability to empower developers to deploy and manage infrastructure across private, hybrid and edge environments. Tinkerbell’s growing community of enterprises, hardware manufacturers and open source developers are contributing code to the project alongside updates from Equinix, helping to add new components, expand documentation and release a technical preview of a new Cluster API provider for Kubernetes.

Tinkerbell is a collection of microservices that together help organizations transform static physical hardware into programmable digital infrastructure regardless of manufacturer, processor architecture, internal components, or networking environment. Its cloud native and workflow-driven approach has been tested in production at Equinix Metal™ with millions of successful provisions of diverse hardware across dozens of global locations.

With Tinkerbell, infrastructure operators and developers can normalize any heterogenous hardware (including x86 and Arm); create powerful workflows to configure and secure private, hybrid or edge infrastructure; deploy their choice of operating system or virtualization software; and manage the life cycle of hardware programmatically.

To get started with Tinkerbell today, visit https://tinkerbell.org/. To watch a livestream demo of Tinkerbell on Wednesday, April 7, 2021, at noon PST, visit: https://www.twitch.tv/equinixmetal

Highlights/Key Facts:

  • The latest release of Tinkerbell includes a number of new or improved capabilities:
    • New Component: Hook is a next-generation in-memory operating system installation environment that builds on extensive experience. Hook was developed with community participation and is based on popular projects including Docker’s LinuxKit. Hook allows end users to quickly rebuild action images, significantly reducing build times from approximately 45 minutes to 90 seconds. Hook also reduces memory footprint while making rebuilding action images for different processor architectures significantly easier. Deployment metrics are available via Prometheus endpoints, allowing operators to monitor their provisioning workflows with their preferred metrics tooling.
    • Composable Workflows via Shared Actions: Using the CNCF Artifact Hub, Tinkerbell users can now share and reuse common workflow actions just as they would with container images on Docker Hub. Common Tinkerbell actions are now written in Go and delivered as binaries to make it easier to author new workflows while reducing memory footprint. These actions can also make use of new functionality from Hook to decrease provisioning times through technologies like kexec.
    • Cluster API for Tinkerbell: By supporting Cluster API, Tinkerbell is adopting the leading community provider for provisioning Kubernetes clusters, increasing interoperability and decreasing the learning curve for those already familiar with Cluster API. After successful community testing, Cluster API for Tinkerbell (CAP-T) will now be extended to implement the full API.
    • Out-of-the-Box Support for Major Operating Systems – Tinkerbell’s support for major operating systems such as VMware ESXi, RedHat Enterprise Linux, Windows Server, Flatcar Linux, Ubuntu, CentOS 8, Debian and NixOS has been tested by the community. New configurable actions provide the ability to deploy any operating system on Tinkerbell as covered in the updated Operating System documentation.
  • The latest Tinkerbell release also includes an updated sandbox that allows users to get up and running with a validated version of the Tinkerbell stack, binaries for both x86 and Arm processors, and introduces a new capability allowing users to swap in and out components. The Tinkerbell sandbox is available through a local development environment on HashiCorp Vagrant Cloud.
  • Tinkerbell has four major components: a DHCP/TFTP server (Boots), a metadata service (Hegel), an in-memory operating system installation environment (Hook) and a workflow engine (Tink). There is also an optional fifth component: a power and boot service (PBnJ) that communicates with the Baseboard Management Controllers (BMCs). The workflow engine is comprised of a server and a command line input (CLI), which communicates via remote procedure calls (gRPC).
  • Tinkerbell was open sourced by Equinix in May 2020 and accepted as a CNCF Sandbox project in November 2020 to empower organizations to deploy and manage diverse physical infrastructure at scale and accelerate their move to hybrid multicloud architectures.
  • Tinkerbell currently powers thousands of daily provisions at Equinix Metal, an interconnected and secure bare metal service. Equinix Metal applies a developer and API-first mindset to foundational infrastructure and provides a fully automated way for digital businesses to access the value of Platform Equinix® via its leading collection of DevOps, open-source and native Equinix Fabric™ integrations.

Quotes:


  • Ross Kukulinski, Product Management Lead for Tanzu Kubernetes Grid, VMware

    “As we push VMware Tanzu into more places, bare metal lifecycling is becoming increasingly important, so we’re excited to see Tinkerbell gain momentum as part of the CNCF and the addition of a Cluster API provider for Tinkerbell. From a Kubernetes perspective, it’s fabulous to see leaders like VMware, Equinix, Microsoft and others rally around Cluster API to pool our development efforts and accelerate the cluster life cycle ecosystem.”

  • Sebastian Scheele, CEO, Kubermatic

    “With Kubermatic Kubernetes Platform, we empower teams worldwide to automate the deployment and operations of multiple Kubernetes clusters in hybrid and multicloud setups. While Kubeadm has solved the problem of running clusters on bare metal, provisioning them remained a challenge. While various tools solve the problem of running Kubernetes on bare metal, Tinkerbell fills a critical gap by facilitating the life cycle of the underlying physical infrastructure in a cloud native and API-driven way.”

  • Mark Coleman, Director of Developer Relations    , Equinix Metal
    “Equinix Metal is passionate about bare metal provisioning and leveraging the power of software to change the world. Community and openness are important to everything we do, from our involvement in the Open19 hardware project to our next-generation provisioning platform, Tinkerbell. We are excited to bring our experience of millions of provisions over half a decade to provide a robust provisioning platform on which our partners and community can create and share workflows to meet any need.”

Additional Resources

About Tinkerbell
Tinkerbell is an open source, all-in-one bare metal provisioning platform for managing data centers at scale worldwide. Developed and maintained by Equinix, and with an active and growing community of open source contributors from across the cloud native ecosystem, Tinkerbell standardizes application management and infrastructure for any architecture. With Tinkerbell, organizations can deploy and manage digital infrastructure from the ground up, from bare metal to Kubernetes, with the components needed to build locally and scale globally. Tinkerbell is licensed under the Apache license, version 2.0. To get started, visit tinkerbell.org.


About Equinix 



Equinix
 (Nasdaq: EQIX) is the world’s digital infrastructure company, enabling digital leaders to harness a trusted platform to bring together and interconnect the foundational infrastructure that powers their success. Equinix enables today’s businesses to access all the right places, partners and possibilities they need to accelerate advantage. With Equinix, they can scale with agility, speed the launch of digital services, deliver world-class experiences and multiply their value.


Forward-Looking Statements 


This press release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements. Factors that might cause such differences include, but are not limited to, the challenges of acquiring, operating and constructing IBX data centers and developing, deploying and delivering Equinix products and solutions, unanticipated costs or difficulties relating to the integration of companies we have acquired or will acquire into Equinix; a failure to receive significant revenues from customers in recently built out or acquired data centers; a failure to complete any financing arrangements contemplated from time to time; competition from existing and new competitors; the ability to generate sufficient cash flow or otherwise obtain funds to repay new or outstanding indebtedness; the loss or decline in business from our key customers; risks related to our taxation as a REIT; and other risks described from time to time in Equinix filings with the Securities and Exchange Commission. In particular, see recent Equinix quarterly and annual reports filed with the Securities and Exchange Commission, copies of which are available upon request from Equinix. Equinix does not assume any obligation to update the forward-looking information contained in this press
release
.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/tinkerbell-an-equinix-open-source-project-empowers-developers-to-deploy-and-manage-foundational-infrastructure-at-global-scale-301263815.html

SOURCE Equinix, Inc.

Posted on

Vertiv Announces Date of First Quarter 2021 Earnings Release and Conference Call

Vertiv Announces Date of First Quarter 2021 Earnings Release and Conference Call

COLUMBUS, Ohio–(BUSINESS WIRE)–
Vertiv Holdings Co (NYSE: VRT), a global provider of critical digital infrastructure and continuity solutions, today announced it will report its first quarter 2021 results before market open on Wednesday, April 28, 2021. Vertiv’s management team will discuss the results during a conference call the same day, starting at 11 a.m. Eastern Time.

A webcast of the live conference call will be available in the Investor Relations section of Vertiv’s website at investors.vertiv.com. A replay of the conference call will also be available for 30 days following the webcast.

About Vertiv Holdings Co

Vertiv (NYSE: VRT) brings together hardware, software, analytics and ongoing services to ensure its customers’ vital applications run continuously, perform optimally and grow with their business needs. Vertiv solves the most important challenges facing today’s data centers, communication networks and commercial and industrial facilities with a portfolio of power, cooling and IT infrastructure solutions and services that extends from the cloud to the edge of the network. Headquartered in Columbus, Ohio, USA, Vertiv employs approximately 20,000 people and does business in more than 130 countries. For more information, and for the latest news and content from Vertiv, visit Vertiv.com.

Category: Financial News

For investor inquiries, please contact:

Lynne Maxeiner

Vice President, Global Treasury & Investor Relations

Vertiv

T +1 614-841-6776

E:  [email protected]

For media inquiries, please contact:

Sara Steindorf

FleishmanHillard for Vertiv

T +1 314-982-1725

E: [email protected]

KEYWORDS: United States North America Ohio

INDUSTRY KEYWORDS: Internet Hardware Data Management Technology Software

MEDIA:

Logo
Logo
Posted on

Aultman Health Foundation to Enhance Medication Management with Omnicell’s Central Pharmacy Dispensing Service

Aultman Health Foundation to Enhance Medication Management with Omnicell’s Central Pharmacy Dispensing Service

Adoption of Technology-Enabled Services and Dispensing Solutions Supports Autonomous Pharmacy Vision

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–
Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that Aultman Health Foundation, a long-term sole source Omnicell partner, has selected the Company’s cloud-based solutions and technology-enabled services to enhance safety and efficiency in central pharmacy and point-of-care dispensing.

Omnicell is committed to transforming the pharmacy care delivery model through the Autonomous Pharmacy, a combination of hardware, software and services that enable providers to improve quality, reduce costs, and increase human efficiencies. With the addition of Omnicell’s Central Pharmacy Dispensing Service, Aultman will leverage technology to automate critical workflows in central pharmacy, supported by certified technicians to optimize the technology and contribute to overall operational efficiency. Aultman also plans to enhance safety and efficiency in patient care areas with XT Automated Dispensing Systems.

Medication management is expensive and error-prone, due in large part to manual and disjointed processes that affect safety and operational challenges, leading to clinician burnout. Studies have found that pharmacists spend 75 percent of their time on non-clinical activities,1 which negatively impacts patient care, employee satisfaction, and turnover.

Omnicell’s Central Pharmacy Dispensing Service combines advanced robotic dispensing technology, certified technicians, best practice and benchmarking tools, change management expertise, and ongoing clinical optimization to maximize value and support clinical, operational, and financial outcomes. Combined with Omnicell’s central pharmacy software platform, Aultman will streamline medication processes from the time a medication is received from the wholesaler to the time it is dispensed to a patient.

“Aultman has a long history with pharmacy automation which has led to significant operational and financial benefits,” said Matt Baldwin, PharmD, system pharmacy director at Aultman Health Foundation. “The addition of Central Pharmacy Dispensing Service will allow us to optimize and maximize our automation technology investment while supporting our goal to provide the safest, most efficient care possible.”

Aultman also plans to upgrade its footprint of automated dispensing systems to support safety and efficiency in clinical care. With streamlined infrastructure capabilities and EHR interoperability, this point-of-care technology is designed to improve medication management workflows, allowing clinicians to spend more time focused on patient care.

Nearly 50 percent of Top 300 U.S. health systems2 are partnering with Omnicell on the journey to the Autonomous Pharmacy, a roadmap to develop a zero-error, fully automated medication management infrastructure. Through Omnicell’s industry-leading medication management platform and portfolio of technology-enabled services, health systems and retail pharmacies are realizing how connected technology and intelligence can help solve for the most pressing challenges in medication management.

“We’re excited to see long-time partners like Aultman Health Foundation recognize the opportunity of the Autonomous Pharmacy to improve efficiencies, outcomes, and performance,” said Scott Seidelmann, executive vice president and chief commercial officer at Omnicell. “We are proud to work together as Aultman moves closer to the fully autonomous pharmacy through solutions like Central Pharmacy Dispensing Service.”

About Aultman

The Aultman Health Foundation is a not-for-profit health care organization serving Stark and surrounding counties. The integrated health care system includes Aultman Hospital, Aultman Orrville Hospital, Aultman Alliance Community Hospital, the locally managed health insurance provider AultCare, The Aultman Foundation and Aultman College. With 1,032 beds, over 700 active physicians and a team of more than 7,000 employees, Aultman is Stark County’s largest provider of health care services. For more information, visit www.aultman.org.

About Omnicell

Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings. Over 7,000 facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. More than 50,000 institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell’s innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions. To learn more, visit www.omnicell.com.

OMCL-G

1Schneider PJ, et al. American Journal of Health-System Pharmacy. 2019;76(15):1127-1141.

2As defined by Definitive Healthcare

Betsy Martinelli

Omnicell, Inc.

(724) 741-8341

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Software Biotechnology Networks Pharmaceutical Internet Health Data Management Technology

MEDIA:

Logo
Logo
Posted on

Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology

Agreement to explore the use of Silo Pharma’s Novel Peptide

Englewood Cliffs, NJ, April 07, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has finalized an agreement to sublicense the technology covered by its recently announced provisional patent applications filed with the United States Patent and Trademark Office (USPTO). The patent applications pertain to Silo Pharma’s novel and proprietary central nervous system (CNS) homing peptides for use in the therapeutic treatment of pain from neuroinflammation in cancer patients.

Eric Weisblum, CEO of Silo Pharma, Inc, stated “We are excited about the next steps of this relationship and the sublicense culminates the previous Letter of Intent announced earlier in February. We are pleased to have a broader team of industry participants working to explore and expand the use of our novel peptides. As a company, we believe that Silo Pharma’s greatest purpose is to create value for its shareholders while working diligently to develop a new novel class of therapeutics for patients suffering from debilitating afflictions, such as cancer.”

About Silo Pharma
 

Silo Pharma. Inc. is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry.  For more information, visit www.silopharma.com

Safe Harbor and Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential” and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.

Investor Relations Contact: 
Hayden IR 
Brett Maas 
646-536-7331 
Email: [email protected]



Posted on

IIROC Trade Resumption – NEO

Canada NewsWire

TORONTO, April 7, 2021 /CNW/ – Trading resumes in:

Company: Neo Performance Materials Inc.

TSX Symbol: NEO

All Issues: Yes

Resumption (ET): ‎8‎:‎00‎ AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions